Results of major myeloma treatment trial published in The Lancet

(SWOG) The addition of bortezomib to a standard two-drug regimen for multiple myeloma patients significantly lengthened the time before their cancer returned, and significantly lengthened their lives, according to clinical trial results in The Lancet.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news